• Biocartis announces market release of SeptiCyte® RAPID test on Idylla™

    Tuesday October 6th 2020

  • Jyseleca® (filgotinib) approved by European Commission for rheumatoid arthritis

    Sunday September 27th 2020

  • Jyseleca® (filgotinib) approved in Japan for rheumatoid arthritis

    Friday September 25th 2020

  • Mithra announces commercial launch of Tibelia® in Canada

    Thursday July 30th 2020

  • US multicenter study shows Idylla™ allows rapid and accurate mutation testing results across different laboratory settings

    Friday June 26th 2020

  • Mithra signs LSA for commercialization of Tibelia® in Liechtenstein and Switzerland

    Thursday June 11th 2020

  • Johnson & Johnson announces acceleration of its COVID-19 vaccine candidate

    Thursday June 11th 2020

  • icometrix lanceert icompanion-platform voor mensen met multiple sclerose

    Tuesday June 2nd 2020

  • Your news here?

  • argenx announces positive topline results from Phase 3 ADAPT Trial of Efgartigimod in patients with Generalized Myasthenia Gravis

    Tuesday May 26th 2020

  • Gilead and Galapagos announce positive topline results of Phase 2B/3 trial of Filgotinib

    Thursday May 21st 2020

  • Mithra and Searchlight Pharma announce filing of new drug submission for Estelle® in Canada

    Wednesday May 20th 2020


Strategic Partners